Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Adverum Biotechnologies, Inc. is not a good value stock. Adverum Biotechnologies, Inc. is not a good growth stock. Adverum Biotechnologies, Inc. is not very popular among insiders. Adverum Biotechnologies, Inc. is a mediocre stock to choose.
Log in to see more information.
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the developm...
ADVM Fundamental Data by TradingView

News

Adverum Biotechnologies reports inducement grants under Nasdaq listing rule
Adverum Biotechnologies reports inducement grants under Nasdaq listing rule

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverum's Board of...\n more…

Analysts Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $28.17
Analysts Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $28.17

Ticker Report Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are covering the stock, Marketbeat.com reports. One...\n more…

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Globe Newswire REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...\n more…

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?

Zacks Investment Research Shares of Adverum Biotechnologies (ADVM) have gained 3.3% over the past four weeks to close the last trading session at $6.94, but there could still be a solid upside left in the stock if short-term...\n more…

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from Analysts
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from Analysts

Zolmax Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company...\n more…